Show simple item record

dc.contributor.authorDichiara, Maria
dc.contributor.authorRuiz Cantero, María del Carmen 
dc.contributor.authorGonzález Cano, Rafael 
dc.contributor.authorCobos del Moral, Enrique José 
dc.date.accessioned2023-09-20T12:29:46Z
dc.date.available2023-09-20T12:29:46Z
dc.date.issued2023-08-03
dc.identifier.citationDichiara, M. et al. Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity. J. Med. Chem. 2023, 66, 16, 11447–11463. [https://doi.org/10.1021/acs.jmedchem.3c00959]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/84530
dc.descriptionThis work was funded by Italian Minister of University and Research project PRIN 2017-201744BN5T. Grant funding (VKA): National Institutes of Health-National Eye Institute-R01EY029409, P30EY00179, National Institutes of Neurological Disorders and Stroke R01NS124784, Unrestricted Grant, Research to Prevent Blindness, New York, NY. This study was partially supported by the Spanish State Research Agency (10.13039/501100011033) under the auspices of MINECO (grant number PID2019-108691RB-I00) and the Andalusian Regional Government (grant CTS109).es_ES
dc.description.abstractThe design and synthesis of a series of 2,7-diazaspiro[4.4]nonanederivatives as potent sigma receptor (SR) ligands, associated withanalgesic activity, are the focus of this work. In this study, affinitiesat S1R and S2R were measured, and molecular modeling studies wereperformed to investigate the binding pose characteristics. The mostpromising compounds were subjected to in vitro toxicitytesting and subsequently screened for in vivo analgesicproperties. Compound 9d (AD258) exhibitednegligible in vitro cellular toxicity and a highbinding affinity to both SRs (K (i)S1R =3.5 nM, K (i)S2R = 2.6 nM), but not for otherpain-related targets, and exerted high potency in a model of capsaicin-inducedallodynia, reaching the maximum antiallodynic effect at very low doses(0.6-1.25 mg/kg). Functional activity experiments showed thatS1R antagonism is needed for the effects of 9d and thatit did not induce motor impairment. In addition, 9d exhibiteda favorable pharmacokinetic profile.es_ES
dc.description.sponsorshipMinistry of Education, Universities and Research (MIUR) PRIN 2017-201744BN5Tes_ES
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Eye Institute (NEI) R01EY029409, P30EY00179es_ES
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Neurological Disorders & Stroke (NINDS) R01NS124784es_ES
dc.description.sponsorshipUnrestricted Grant, Research to Prevent Blindness, New York, NYes_ES
dc.description.sponsorshipSpanish Government PID2019-108691RB-I00es_ES
dc.description.sponsorshipAndalusian Regional Government CTS109es_ES
dc.language.isoenges_ES
dc.publisherACS Publicationses_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleDiscovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activityes_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1021/acs.jmedchem.3c00959
dc.type.hasVersionVoRes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional